Funded by Unitaid, the IMPAACT4TB Consortium works in collaboration with the World Health Organisation(WHO) and focused primarily on providing safer, shorter TPT (3HP and 1HP) that is affordable and accessible to target populations: People living with HIV, children under 5 years and all household contacts.
The IMPAACT4TB Consortium members have exceptional experience in shaping markets, strengthening supply chain management and supporting National TB Programmes in high-burden countries.
Today, in Phase 2, we’re uncovering crucial evidence for often overlooked populations, such as children, pregnant women, and household contacts of TB cases. Our consortium has been instrumental in reshaping the TB landscape with short-course TPT, accelerating progress toward UNHLM targets and the ultimate goal of ending TB!
The price dropped from $72 in 2017 to $14,25 in 2022 and $9,99 in 2023 for the FDC. 1HP is available at $17- $18.
Increased from 180k patient courses in 2018 to over 4,5 million in 2023.
Over 4,5 million patient courses of rifapentine-based TB preventive treatments have been purchased across 78 countries. In total, 138 countries now have access to purchase 3HP.
From one (1) country in 2018 to over seventy-eight (78) countries procuring 3HP in 2023.
The IMPAACT4TB Project has moved into the next phase to generate more evidence for vulnerable and undeserved populations.
